Table 4. Outcome data by NRAS and KRAS... | American Society of Hematology

Table 4.

Outcome data by NRAS and KRAS mutation status for patients treated within the MRC AML10 and AML12 clinical trials

	*NRAS*					*KRAS*
	Mutant, %	Nonmutant, %	P	Mutant, %	Nonmutant, %	P
Induction death	9	8	.7	8	8	.9
Resistant disease	10	9	.8	3	10	.16
Complete remission (CR)	82	83	.6	90	82	.2
5-y death in CR	18	18	.4	19	18	.7
5-y relapse rate	48	48	.6	44	47	.8
5-y disease-free survival	42	42	.9	45	43	.9
5-y overall survival	43	42	.9	49	43	.5

	*NRAS*					*KRAS*
	Mutant, %	Nonmutant, %	P	Mutant, %	Nonmutant, %	P
Induction death	9	8	.7	8	8	.9
Resistant disease	10	9	.8	3	10	.16
Complete remission (CR)	82	83	.6	90	82	.2
5-y death in CR	18	18	.4	19	18	.7
5-y relapse rate	48	48	.6	44	47	.8
5-y disease-free survival	42	42	.9	45	43	.9
5-y overall survival	43	42	.9	49	43	.5